Advanced searches left 3/3

Chronic Kidney Disease - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 15 January 2023

* If you want to update the article please login/register

The effect of pharmacist‐led interventions on the management and outcomes in chronic kidney disease (CKD): A systematic review and meta‐analysis protocol

Background and Aims Chronic kidney disease is a chronic illness that results in a decline in kidney function with time. CKD prevention includes determining cardiovascular risk factors and addressing CKD-related complications. Pharmacist pharmacists are always playing a role in CKD care, from the optimization of risk factors to patient education.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1064


Cerebrovascular pulsatility index is higher in chronic kidney disease

Patients with chronic kidney disease, including cerebrovascular disease, are more likely to die from cardiovascular disease, particularly cerebrovascular disease, than to progress to end-stage kidney disease in 2010. We compared middle cerebral artery blood pressure responses to hypercapnia and MCA pulsatility index in patients with stage 3 CKD vs. age-matched healthy controls using transcranial Doppler. We also used the NIH cognitive toolbox, measured carotidu2010femoral pulse, and estimated ex vivo nitric oxide and reactive oxygen species production from human brain endothelial cells incubated with serum obtained from study participants. Patients with CKD vs. controls were higher in patients with CKD compared to standard controls; however, normalized MCA blood flow responses to hypercapnia did not differ among groups. These results show that impaired kidney function is associated with increased cerebrovascular stiffness, which may contribute to the observed elevated risk of cognitive impairment in patients with CKD.

Source link: https://onlinelibrary.wiley.com/doi/10.14814/phy2.15561


High physical activity alleviates the adverse effect of higher sedentary time on the incidence of chronic kidney disease

Background: Background The prevalence of chronic kidney disease is increasing with inadequate physical activity. This research was designed to investigate the effects of PA and sedentary time on renal function and CKD in the Korean middle-aged population in middle to early 2010.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13167


The G protein‐coupled receptor ligand apelin‐13 ameliorates skeletal muscle atrophy induced by chronic kidney disease

In CKDu2010induced skeletal muscle atrophy, we investigated the role and effectiveness of the apelin U2013Apj device. Results Skeletal muscle atrophy progressed over time after nephrectomy at 12 weeks, as shown by a significant rise in atroginu20101 and myostatin mRNA expression in the gastrocnemius muscle and a decrease in lower limb skeletal muscle mass, as demonstrated by a significant decrease in lower limb skeletal muscle mass. The administration of apelin at 1. 0 u03bcmol/kg to CKD mice for four weeks reduced the increase of atroginu2011 and myostatin, increased apelin and Apj mRNA expression at 30 min after the apelin administration and significant weight loss, as well as a decrease in the cross-sectional area of hindlimb skeletal muscle muscle. Conclusions This research found the association of the Apj endogenous ligand axis with skeletal muscle atrophy in CKD and the possibility of therapeutic targeting of the apelin u2013Apj device for the first time.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13159


Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus

Evidence shows that sodium dehydration inhibitors, such as dapagliflozin, may slow renal function in patients with type 2 diabetes mellitus and chronic kidney disease. T2DM, adult with T2DM, healthy subjects, and pediatric patients with T2DM were all included in clinical studies, including adult adults with or without T2DM, adults with or without T2DM, adults with T2DM, healthy subjects, and pediatric patients with T2DM. Patients with CKD with and without T2DM were not significantly different between patients with and without T2DM. When compared to adult patients with T2DM without CKD, adult patients with T2DM were 1. 6 billionfold higher. With an estimated glomerular filtration rate of 15 mL/min/1. 73 m2 in patients with CKD and estimated renal clearance of dapagliflozin decreased relative to decreased renal clearance, median AUC was 2. 4 percent higher in patients with estimated glomerular filtration rate of 15. 00 m2 in patients with estimated glomerular filtration rate of 15. 73 m2 in patients with estimated glomerular filtration rate of 15. 73 percent in patients with estimated glomerular m2 2. 4 glomerular m2 glomerular m2 in patients with estimated 2. 4 m2 3. 2 m2 2. 4 2. 4 2. 4 2. 4 3. 2 2. 4 2. 4 4. 0 4. 1 2. 4 2. 4 m2 2. 4 2. 4 2. 4 2. 1 2. 4 2. 4 3. 1 2. 4 2. 4 2. 2 2. 2 3. 2 m2 2. 4 2. 4 4. 2 3. 2 2. 9 1. 9 m2 2. 8 2. 1 4. 3 1. 7 4. 0 3. 4 2. 4 3. 3.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jcph.2196


Deletion of the P2Y2 receptor aggravates internal elastic lamina calcification in chronic kidney disease mice through upregulation of alkaline phosphatase and lipocalin‐2

This study explores whether deletion of the P2Y2 receptor may influence arterial media calcification in CKD mice. The mice were divided into: wild type mice with normal renal function, P2Y2Ru2212 mice with normal renal function, wild type mice with CKD, and P2Y2Ru2212 mice with CKD. All CKD groups suffered from chronic renal failure as shown by elevated serum creatinine and phosphorus levels. However, deletion of the P2Y2 receptor makes CKD mice more vulnerable to the formation of calcification in the heart and aorta. This P2Y2Ru2212/u2212-mediated rise in CKDu2010-related arterial media calcification was attributed to an increase in arterial media calcification, including alkaline phosphatase and inflammatory molecules interleukin 2 and lipocalin 2. The P2Y2 receptor can be used as a promising therapeutic target for combating CKD-related arterial media calcification.

Source link: https://onlinelibrary.wiley.com/doi/10.1096/fj.202201044R

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions